. . . . "U l\u00E9\u010Den\u00FDch my\u0161\u00ED byla detekov\u00E1na zv\u00FD\u0161en\u00E1 produkce cytokin\u016F, ale nebyl nalezen rozd\u00EDl v Th1/Th2 polarizaci imunitn\u00ED odpov\u011Bdi. Ve slezin\u00E1ch my\u0161\u00ED nesouc\u00EDch TC-1 (MHC I+), ale ne TC-1/A9 (MHC I\u2013) n\u00E1dory, byly nalezeny cytotoxick\u00E9 CD8+ bu\u0148ky. Ve slezin\u00E1ch l\u00E9\u010Den\u00FDch my\u0161\u00ED nesouc\u00EDch TC-1/A9 n\u00E1dory, byly naopak nalezena NK aktivita detekovateln\u00E1 jako l\u00FDza NK senzitivn\u00EDch YAC-1 bun\u011Bk. Sn\u00ED\u017Een\u00FD po\u010Det CD4+ a CD8+ bun\u011Bk p\u0159etrv\u00E1val I po l\u00E9\u010Db\u011B; zat\u00EDm co procento CD25+/CD4+ T regula\u010Dn\u00EDch bun\u011Bk se nem\u011Bnilo. Chemoterapie vedla ke zv\u00FD\u0161en\u00ED po\u010Dtu imunosupresivn\u00EDch nezral\u00FDch myeloidn\u00EDch bun\u011Bk Gr-1+/CD11b+ (IMC) ve slezin\u00E1ch l\u00E9\u010Den\u00FDch zv\u00ED\u0159at. Jejich akumulace by mohla b\u00FDt zodpov\u011Bn\u00E1 za zv\u00FD\u0161en\u00ED imunitn\u00ED odpov\u011B\u010Fi po adjuvantn\u00ED l\u00E9\u010Db\u011B pomoc\u00ED IL-12."@cs . . . "IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets"@en . "Bieblov\u00E1, Jana" . "HPV 16; MHC class I-positive and -deficient tumours; immature myeloid cells"@en . "Imunoterapie minim\u00E1ln\u00ED zbytkov\u00E9 choroby interleukinem 12 na my\u0161\u00EDm modelu n\u00E1dor\u016F asociovan\u00FDch s virem HPV 16: Indukce imunitn\u00ED odpov\u011Bdi, produkce cytokin\u016F a kinetika subpopulac\u00ED imunn\u00EDch bun\u011Bk"@cs . . "International Journal of Oncology" . "4"^^ . . . "Buben\u00EDk, Jan" . "4"^^ . . "GR - \u0158eck\u00E1 republika" . "IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets" . "32" . "2" . . . "371396" . . "Indrov\u00E1, Marie" . "Reini\u0161, Milan" . "Imunoterapie minim\u00E1ln\u00ED zbytkov\u00E9 choroby interleukinem 12 na my\u0161\u00EDm modelu n\u00E1dor\u016F asociovan\u00FDch s virem HPV 16: Indukce imunitn\u00ED odpov\u011Bdi, produkce cytokin\u016F a kinetika subpopulac\u00ED imunn\u00EDch bun\u011Bk"@cs . "1019-6439" . . . "RIV/68378050:_____/08:00306790" . "IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets"@en . . "[AA8B92957B40]" . "P(GA301/06/0774), Z(AV0Z50520514)" . . . "In this model, upregulation of cytokine production was detected, compared to the animals without tumours. But, no differences in Th1/Th2 polarization of the immune responses were observed. In the spleens of TC-1 (MHC class I+) but not of TC-1/A9 (MHC class I\u2013) treated tumour-bearing animals, the cytotoxic CD8+ cells were found. In the spleens of TC-1/A9 but not of TC-1 tumour-treated animals, the NK activity measured as the lysis of NK-sensitive YAC-1 targets was detected. Downregulation of the CD4+ and CD8+ subpopulations were not restored after therapy. The percentage of CD25+/CD4+ T regulatory cells in lymph nodes remained unchanged. The chemotherapy led to upregulation of immunosuppressive immature myeloid Gr-1+/CD11b+ (IMC) cells in the spleens of treated animals. The accumulation of IMC was significantly decreased after subsequent IL-12 immunotherapy. That elimination may be responsible for the improvement of antitumour responses after adjuvant IL-12 vaccination."@en . "IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets" . "RIV/68378050:_____/08:00306790!RIV09-AV0-68378050" . "000252620900025" . "In this model, upregulation of cytokine production was detected, compared to the animals without tumours. But, no differences in Th1/Th2 polarization of the immune responses were observed. In the spleens of TC-1 (MHC class I+) but not of TC-1/A9 (MHC class I\u2013) treated tumour-bearing animals, the cytotoxic CD8+ cells were found. In the spleens of TC-1/A9 but not of TC-1 tumour-treated animals, the NK activity measured as the lysis of NK-sensitive YAC-1 targets was detected. Downregulation of the CD4+ and CD8+ subpopulations were not restored after therapy. The percentage of CD25+/CD4+ T regulatory cells in lymph nodes remained unchanged. The chemotherapy led to upregulation of immunosuppressive immature myeloid Gr-1+/CD11b+ (IMC) cells in the spleens of treated animals. The accumulation of IMC was significantly decreased after subsequent IL-12 immunotherapy. That elimination may be responsible for the improvement of antitumour responses after adjuvant IL-12 vaccination." . . . "9"^^ .